Compare AI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | OGN |
|---|---|---|
| Founded | 2009 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2020 |
| Metric | AI | OGN |
|---|---|---|
| Price | $9.68 | $13.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 5 |
| Target Price | ★ $14.00 | $11.40 |
| AVG Volume (30 Days) | ★ 4.5M | 2.6M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | $250,268,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $14.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.68 | $5.69 |
| 52 Week High | $20.22 | $13.76 |
| Indicator | AI | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 72.40 |
| Support Level | $9.81 | $13.46 |
| Resistance Level | $10.73 | N/A |
| Average True Range (ATR) | 0.42 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.96 | 93.18 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions, namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications; C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications; and C3 Generative AI, which combines the utility of large language models. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.